Product information and disease descriptionPlace of product in therapyApproaches to treatment
Place in treatment, anticipated use, and care setting
1 evidence topic · 5 sources
Summary
The studied use of relutrigine is as an investigational treatment for SCN2A- and SCN8A-related DEEs in participants already receiving antiseizure medications. In EMBOLD cohort 2, 34 participants exposed to relutrigine, representing 67%, were taking three to six ASMs at baseline. The manufacturer describes an oral or G/J-tube liquid formulation. Expanded-access requests require submission by the treating physician and are considered individually. These data describe study use and access arrangements, not an approved treatment position.